Report Detail
Global Rezvilutamide Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4733777 |
- 24 August, 2026 |
- Global |
- 73 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Rezvilutamide market size was valued at US$ 193 million in 2025 and is forecast to a readjusted size of US$ 598 million by 2032 with a CAGR of 13.1% during review period.
In 2025, global Rezvilutamide production reached approximately 2.1 million units.Relugolix is an orally administered small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. It exerts its therapeutic effects by inhibiting the hypothalamic–pituitary–gonadal (HPG) axis, thereby rapidly reducing the levels of testosterone or estrogen in the body. The drug is widely used in the treatment of hormone-dependent conditions, such as prostate cancer, uterine fibroids, and endometriosis. Compared with traditional GnRH agonists, relugolix has a faster onset of action and does not cause an initial hormone “flare-up” effect, offering improved safety and tolerability. It represents an important advancement in the field of endocrine therapy in recent years.
Relugolix, as a new-generation oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is in a rapidly growing phase within the hormone-regulating therapeutics market. Driven by the increasing incidence of hormone-dependent diseases such as prostate cancer, uterine fibroids, and endometriosis, along with population aging and the advancement of precision medicine, demand for related treatments continues to rise steadily. Compared with traditional injectable GnRH agonists, relugolix offers advantages including oral administration, rapid onset of action, and no hormone “flare-up” effect, significantly improving patient compliance and optimizing the treatment experience, thereby enhancing its clinical penetration. Meanwhile, with the continuous expansion of indications and the development of combination therapies, its market potential in both male oncology and women’s health is further expanding. Overall, relugolix is expected to maintain strong growth in the future and become an important driver in the field of endocrine therapy.
This report is a detailed and comprehensive analysis for global Rezvilutamide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Rezvilutamide market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Rezvilutamide market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Rezvilutamide market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Rezvilutamide market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rezvilutamide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rezvilutamide market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Myovant Sciences, Pfizer, Aurisco Pharmaceutical, Jiangsu Hengrui Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Rezvilutamide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1 g
5 g
10 g
Market segment by Dosage Form
Tablet
Powder
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Prostate Cancer
Uterine Fibroids
Endometriosis
Others
Major players covered
Myovant Sciences
Pfizer
Aurisco Pharmaceutical
Jiangsu Hengrui Medicine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rezvilutamide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Rezvilutamide, with price, sales quantity, revenue, and global market share of Rezvilutamide from 2021 to 2026.
Chapter 3, the Rezvilutamide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rezvilutamide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Rezvilutamide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Rezvilutamide.
Chapter 14 and 15, to describe Rezvilutamide sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Rezvilutamide Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 1 g
- 1.3.3 5 g
- 1.3.4 10 g
- 1.4 Market Analysis by Dosage Form
- 1.4.1 Overview: Global Rezvilutamide Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.4.2 Tablet
- 1.4.3 Powder
- 1.5 Market Analysis by Sales Channels
- 1.5.1 Overview: Global Rezvilutamide Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.5.2 Hospital
- 1.5.3 Retail
- 1.5.4 Online
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Rezvilutamide Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Prostate Cancer
- 1.6.3 Uterine Fibroids
- 1.6.4 Endometriosis
- 1.6.5 Others
- 1.7 Global Rezvilutamide Market Size & Forecast
- 1.7.1 Global Rezvilutamide Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Rezvilutamide Sales Quantity (2021-2032)
- 1.7.3 Global Rezvilutamide Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Myovant Sciences
- 2.1.1 Myovant Sciences Details
- 2.1.2 Myovant Sciences Major Business
- 2.1.3 Myovant Sciences Rezvilutamide Product and Services
- 2.1.4 Myovant Sciences Rezvilutamide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Myovant Sciences Recent Developments/Updates
- 2.2 Pfizer
- 2.2.1 Pfizer Details
- 2.2.2 Pfizer Major Business
- 2.2.3 Pfizer Rezvilutamide Product and Services
- 2.2.4 Pfizer Rezvilutamide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Pfizer Recent Developments/Updates
- 2.3 Aurisco Pharmaceutical
- 2.3.1 Aurisco Pharmaceutical Details
- 2.3.2 Aurisco Pharmaceutical Major Business
- 2.3.3 Aurisco Pharmaceutical Rezvilutamide Product and Services
- 2.3.4 Aurisco Pharmaceutical Rezvilutamide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Aurisco Pharmaceutical Recent Developments/Updates
- 2.4 Jiangsu Hengrui Medicine
- 2.4.1 Jiangsu Hengrui Medicine Details
- 2.4.2 Jiangsu Hengrui Medicine Major Business
- 2.4.3 Jiangsu Hengrui Medicine Rezvilutamide Product and Services
- 2.4.4 Jiangsu Hengrui Medicine Rezvilutamide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Jiangsu Hengrui Medicine Recent Developments/Updates
3 Competitive Environment: Rezvilutamide by Manufacturer
- 3.1 Global Rezvilutamide Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Rezvilutamide Revenue by Manufacturer (2021-2026)
- 3.3 Global Rezvilutamide Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Rezvilutamide by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Rezvilutamide Manufacturer Market Share in 2025
- 3.4.3 Top 6 Rezvilutamide Manufacturer Market Share in 2025
- 3.5 Rezvilutamide Market: Overall Company Footprint Analysis
- 3.5.1 Rezvilutamide Market: Region Footprint
- 3.5.2 Rezvilutamide Market: Company Product Type Footprint
- 3.5.3 Rezvilutamide Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Rezvilutamide Market Size by Region
- 4.1.1 Global Rezvilutamide Sales Quantity by Region (2021-2032)
- 4.1.2 Global Rezvilutamide Consumption Value by Region (2021-2032)
- 4.1.3 Global Rezvilutamide Average Price by Region (2021-2032)
- 4.2 North America Rezvilutamide Consumption Value (2021-2032)
- 4.3 Europe Rezvilutamide Consumption Value (2021-2032)
- 4.4 Asia-Pacific Rezvilutamide Consumption Value (2021-2032)
- 4.5 South America Rezvilutamide Consumption Value (2021-2032)
- 4.6 Middle East & Africa Rezvilutamide Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Rezvilutamide Sales Quantity by Type (2021-2032)
- 5.2 Global Rezvilutamide Consumption Value by Type (2021-2032)
- 5.3 Global Rezvilutamide Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Rezvilutamide Sales Quantity by Application (2021-2032)
- 6.2 Global Rezvilutamide Consumption Value by Application (2021-2032)
- 6.3 Global Rezvilutamide Average Price by Application (2021-2032)
7 North America
- 7.1 North America Rezvilutamide Sales Quantity by Type (2021-2032)
- 7.2 North America Rezvilutamide Sales Quantity by Application (2021-2032)
- 7.3 North America Rezvilutamide Market Size by Country
- 7.3.1 North America Rezvilutamide Sales Quantity by Country (2021-2032)
- 7.3.2 North America Rezvilutamide Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Rezvilutamide Sales Quantity by Type (2021-2032)
- 8.2 Europe Rezvilutamide Sales Quantity by Application (2021-2032)
- 8.3 Europe Rezvilutamide Market Size by Country
- 8.3.1 Europe Rezvilutamide Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Rezvilutamide Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Rezvilutamide Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Rezvilutamide Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Rezvilutamide Market Size by Region
- 9.3.1 Asia-Pacific Rezvilutamide Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Rezvilutamide Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Rezvilutamide Sales Quantity by Type (2021-2032)
- 10.2 South America Rezvilutamide Sales Quantity by Application (2021-2032)
- 10.3 South America Rezvilutamide Market Size by Country
- 10.3.1 South America Rezvilutamide Sales Quantity by Country (2021-2032)
- 10.3.2 South America Rezvilutamide Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Rezvilutamide Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Rezvilutamide Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Rezvilutamide Market Size by Country
- 11.3.1 Middle East & Africa Rezvilutamide Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Rezvilutamide Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Rezvilutamide Market Drivers
- 12.2 Rezvilutamide Market Restraints
- 12.3 Rezvilutamide Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Rezvilutamide and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Rezvilutamide
- 13.3 Rezvilutamide Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Rezvilutamide Typical Distributors
- 14.3 Rezvilutamide Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Rezvilutamide. Industry analysis & Market Report on Rezvilutamide is a syndicated market report, published as Global Rezvilutamide Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Rezvilutamide market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
